Abstract:

Background: Peripheral neuropathy is characterized by distal damage to neurons along PNS which consists of loss of function. This would result from various factors.

Chemotherapy Induced Peripheral Neuropathy (CIPN), a side effect of chemotherapy decreasing quality of life. There are various mechanisms by which these cause CIPN are neuronal structural and functional alterations.

Method: Background searches into peripheral neuropathy and the chemotherapeutic agents that induce CIPN and their mechanisms were done from a series of journal databases.

Treatment options were sought from the same databases dating between 2003 and 2019. From this the therapeutic options that have been explored and tried and the updates to these have been enumerated a discussed.

Discussion: CIPN manifests from a heterogenous group of aetiologies. One standardized treatment option is not available for proper treatment of CIPN. Research over the years has produced methods of prevention and treatment for CIPN patients, including the use of preventative therapy, polypharmacy and some specific first line drugs. Nonpharmacological methods of treating CIPN comprises of the recent use of medicinal plants and complementary therapies for severe pain relief and better quality of life for these patients.

Future Scope of Studies: Over the past decade, despite many efforts to develop a standardized treatment for CIPN, there has been little success. As a result, many more future studies are strongly indicated.

Keywords: Chemotherapy Induced Peripheral Neuropathy, Chemotherapy, Neuralgia, Neuropathy Mechanisms, Peripheral Neuropathy Therapy.

References:

[1].St Sauver, J.L., Warner, D.O., Yawn, B.P. et al. Why patients visit their doctors: assessing the most prevalent conditions in a defined American population. Mayo Clin Proc. 2013; 88: 56–67.

[2].Hsiao, C.J., Donald, K., Cherry, D.K., Beatty, P.C., and Rechtsteiner, E.A. National Ambulatory Medical Care Survey: 2007 summary. Natl Health Stat Report. 2010; 27: 1–32.

[3].Martyn, C.N. and Hughes, R.A. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997; 62: 310–318.

[4].Italian General Practitioner Study Group (IGPSG). Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions, I: Prevalence and general characteristics of the sample. Neurology. 1995; 45: 1832–1836.

[5].Peter G. Erdmann, PT, MSc Laurien L. Teunissen, Frank R. van Genderen, Nicolette C. Notermans, Eline Lindeman, Paul J. M. Helders, PT, et al Functioning of patients with chronic idiopathic axonal polyneuropathy (CIAP).J Neurol. 2007 Mar; 254(9): 1204–1211.

[6].Hanewinckel R, Ikram MA, Van Doorn PA. Peripheral neuropathies. Handb Clin 2016; 138:263-82.

[7].Yan WX, Archelos JJ, Hartung H-P, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001; 50:286–292.

[8].Schenone A, Mancardi GL. Molecular basis of inherited neuropathies. CurrOpin Neurol. 1999; 12:603–616.

[9].Stabler, S.P. Vitamin B₁₂ deficiency. N Engl J Med. 2013; 368: 149–160.

[10]. Saperstein, D.S., Wolfe, G.I., Gronseth, G.S. et al. Challenges in the identification of cobalamin-deficiency polyneuropathy. Arch Neurol. 2003; 60: 1296–1301.

[11]. Ammendola A, Tata MR, Aurilio C, et al. Peripheral neuropathy in chronic alcoholism: a retrospective cross-sectional study in 76 subjects. Alcohol 2001; 36:271-275.

[12]. Janet Schloss, Maree Colosimo. B Vitamin Complex and Chemotherapy-Induced Peripheral Neuropathy. Integrative Care. 2017.

[13]. Pardo CA, Mcarthur JC, Griffin JW. HIV neuropathy: Insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst. 2001; 27:21–27.

[14].  Argriou A. A., Kyritsis A. P., Makarsoris T. and Kalofonos H. P. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of literature. Cancer Manag Res. 2014 Mar 19; (6) 135-147. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964029/#b87-cmar-6-135.

[15]. Han Y. and Smith M. T. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front. Pharmacol. 2013 Dec 18. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2013.00156/full.

[16].  Jeon H.J., Woo J. H., Lee H. Y., Park K. J., Choi H. J. Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer. J Korean Soc Coloproctol. 2011 Jun; (27) 140-146. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145885/

[17].  Tesniere A^., Schlemmer F., Boige V., Kepp O., Martins I., and Ghiringhelli F. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010 Jan 28; (29). Available from: https://www.ncbi.nlm.nih.gov/pubmed/19881547/.

[18]. Todd R. C., Lippard S. J. Inhibition of transcription by platinum antitumor compounds. Matallomics. 2009; (4). Available from: https://www.ncbi.nlm.nih.gov/pubmed/20046924/.

[19]. Dasari S., Tchounwou P. B. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014 Oct 5; (740). Available from: https://www.ncbi.nlm.nih.gov/pubmed/25058905/.

[20].  Starobova H., Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front. Mol. Neurosci. 2017 May 31; (10). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450696/#B51.

[21].  Gelletti E., Mangnani M., Renzuli M. L., Botta M. Plaxitaxel and doxetaxel resistance: molecular mechanisms and development of new generations taxanes. ChemMedChem. 2007 Jul; (7). Available from: https://www.ncbi.nlm.nih.gov/pubmed/17530726.

[22].  Himes R. H., kersey R. N., Hellr-Bettinger I., Sanson F. E. Action of the Vinca Alkaloids Vincristine, Vinblastine, and Desacetyl Vinblastine Amide on Microtubules in Vitro. Cancer Research. 1976 October. Available from: http://cancerres.aacrjournals.org/content/36/10/3798.short.

[23]. Gan P. P., McCaroll J. A., Poúha S. T., Kamath K., Jordan M. A., Kavallaris M. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of beta III tubulin. Mol. Cancer Thar. 2010 May; (5). Available from: https://www.ncbi.nlm.nih.gov/pubmed/20442307/.

[24]. Cavaletti G., Gilardini A., Canta A., Rigamonti L., Rodriguez-Mendez V., Creesa C. et al. Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. Experimental Neurology. 2007 March; (204) 317-325. Available from: https://www.sciencedirect.com/science/article/pii/S0014488606006170?via%3Dihub

[25]. Argyriou A. A., Iconomou G., Kalofanos H. P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008 (4) 1593-1599. Available from: http://www.bloodjournal.org/content/112/5/1593?sso-checked=true.

[26].  Raghavendra V., Tanga F., de Leo J. A. Inhibtion of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Thar. 3003 May 6; (2). Available from: https://www.ncbi.nlm.nih.gov/pubmed/12734393/.

[27].      Liu C. C., Lu N., Cui Y., yang T., Zhao Z. Q., Xin W. J., Liu X. G. prevention of paxitaxel-induced allondyia by minocycline: Effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol Pain. 2010 Nov 5; (76). Available from: https://www.ncbi.nlm.nih.gov/pubmed/21050491/.

[28]. Wang X. M., Lehky T. J., Brell J. M., Dorsey S. G. Discovering cytokine as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012 Jul; (59) 3-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22537849/.

[29].  Old E. A., Nadkarni S. Grist J., Gentry C., Bevan S., Kim K. W. Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain. J Clin Invest. 2014 May; (124) 2023-2036. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24743146/.

[30].  Chatterjee S., Behman Azad B., Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014; (124) 31-82. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25287686/.

[31].  Deuis J. R., Zimmermann K., Romanovsky A. A., Possani L. D., Cabot P. J., Vetter I. An animal model of oxaliplatin-induced cold allondyia reveals a crucial role for Nav1.6 in peripheral pain pathways. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23711479/.

[32].  Kidd J. F., Pilkington M. F., Schell M. J., Forgarty K. E., Skepper J. N., Taylor C. W., Thorn P. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem. 2002 Feb 22; (277) 6504-6510. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11724773/.

[33]. McDonald E. S., Windebank A. J. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not as fas receptor signalling. Neurobiol Dis. 2002 Mar; (9) 220-233. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11895373/.

[34]. Flatter S. J., Bennett G. J. Studies of peripheral sensory nerves in paclitaxel;-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006 Jun; (122) 245-257. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450696/#B77.

[35]. Sittl R., Lampert A., Huth T., Schuy E. T., Link A. S., Fleckenstein J., Alzhemier C. et al. Anticancer drug oxaliplatin induces acute cooling-aggrevated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Sci U S A. 2012 Apr 24; (109) 6704-6709. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22493249/.

[36]. Zhange H., Dougherty P. M. Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. Anesthesiology. 2014 Jun; (120) 1463-1475. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24534904/

[37]. Krzysztof Brzeziński. Chemotherapy-induced peripheral neuropathy. Part II. Prevention. WspolczesnaOnkol 2012; 16 (3): 258–261.

[38].   Michael H. Ossipov, Frank Porreca. Challenges in the Development of Novel Treatment Strategies for Neuropathic Pain. The Journal of the American Society for Experimental Neuro Therapeutics. October 2005; Vol. 2: 650–661.

[39]. Judith A. Paice. Mechanisms and Management of Neuropathic Pain in Cancer. The Journal of Supportive Oncology. July/August 2003 Volume 1, Number 2.

[40]. Thomas J. Kaley and Lisa M. DeAngelis. Therapy of chemotherapy-induced peripheral neuropathy. British Journal of Hematology. 2009: 145, 3–14.

[41]. Meghna S. Trivedi, MD, Dawn L. Hershman, MD, MS, Katherine D. Crew, MD, MS. Management of Chemotherapy-Induced Peripheral Neuropathy. The American Journal of Hematology/oncology. Jan2015.

[42].  Rose N. Kajih, Clarence D. Moore. Management of Chemotherapy-Induced Peripheral Neuropathy. US Pharm. 2015; 40(1): HS5-HS10.